A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Within the legacy portfolio, higher sales of Eliquis were offset by the expected ... We've also seen a number of NCCN guidelines updated for your reimbursement question to include Opdivo Qvantig ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Methods: We analyzed all ischemic stroke patients with atrial fibrillation and impaired renal function (creatinine clearance < 30) who were discharged on antithrombotics in the Get with the Guidelines ...

Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...

With these anticipated label enhancements, EYLEA HD will offer the broadest set of retinal disease indications with the greatest dose and flexibility ... non-inferior to apixaban, while REGN9933 ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed ... and has been administered in a twice-daily dosing regimen in clinical trials without the need for ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

Medicare typically covers Eliquis through Medicare Advantage Part C or Medicare Part D prescription drug coverage plans. The cost of Eliquis can depend on the type of plan, the formulary tier ...